Jade Whiting – Argenica Therapeutics

2026

11 Jun 2026Argenica Clears Final FDA Safety Test With No Cardiac Risk to Lead Stroke DrugReference: Stockwire
11 Jun 2026Biotech firms’ big fear: Labor tax changes will drive trials offshoreReference: The Australian
11 Jun 2026Argenica Clears Final FDA Safety Hurdle for ARG-007, Eyes Phase 2b Trial StartReference: Middle.
10 Jun 2026Argenica Secures Xaranetide as Global Name for Lead Stroke Drug ARG-007Reference: StockwireX
06 May 2026Biocurious: With its drug candidate AGN-007, Argenica has a licence to thrillReference: Stockhead
17 Mar 2026Argenica boosts cash reserves with $3.97m R&D rebate to advance stroke drug
17 Mar 2026Argenica Lands $3.97M Tax Rebate, Lifting Cash to $9M Without DilutionReference: StockWireX
17 Mar 2026Argenica’s $3.97M Rebate Raises Stakes for Upcoming Stroke Trial SuccessReference: Middle.
19 Feb 2026Overcoming Operational Hurdles in a High-Stakes Stroke TrialReference: ProPharma
18 Feb 2026Sophisticated AI analysis reveals efficacy of neuroprotective drug for severe strokeReference: Perron Institute